Lead Product(s) : Aspirin,Ramipril,Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : CNIC
Deal Size : Inapplicable
Deal Type : Inapplicable
The Polypill Reduces Cardiovascular Mortality By 33% In Patients Treated After Myocardial Infarction
Details : The polypill includes three drugs (aspirin, an ACE inhibitor, and a statin), is effective at preventing secondary adverse cardiovascular events in people who have previously had a heart attack.
Product Name : Polypill
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2022
Lead Product(s) : Aspirin,Ramipril,Simvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : CNIC
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ramipril
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
UC San Diego to Assess Hypertension Drug Ramipril for Covid-19
Details : Ramipril will be assessed for its potential to decrease the severity of Covid-19, lower intensive care unit admission rates, mechanical ventilators use, and all-cause mortality.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2020
Lead Product(s) : Ramipril
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
